1University of Minnesota, Minneapolis, MN.
1Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, Iowa. 2Holden Comprehensive Cancer Center, University of Iowa, ...
1Department of Biological Sciences, New York City College of Technology, City University of New York, Brooklyn, New York. 2Biology and Computer PhD Programs, The CUNY Graduate Center, City University ...
1Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Freiburg University Medical Center, Freiburg, Germany.
Abstract. TNG462 is a clinical-stage, MTA-cooperative PRMT5 inhibitor currently being evaluated in an ongoing phase I/II clinical trial for solid tumors with MTAP loss. Approximately 10-15% of all ...
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Bristol Meyers Squib, Seattle, WA.
Affinity Biopharmaceutical Co., Ltd., Shanghai, China.
Cancer Research | 85 | 8_Supplement_1 | April 2025Journal Archive Cancer Research (1941-Present; volumes 1-current) Published twice monthly since 1987. From 1941-1986, published monthly. (ISSN ...
1Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
1Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany. 2Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer ...
1Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback